Suven Life Sciences has received two patents viz., US7,718,690 and US 7,781,476 for its New Chemical Entities (NCEs) from US Patent Office for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2022.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.
With these new patents, Suven has total of 8 granted US patents on NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
(Source: Pharmabiz)
No comments:
Post a Comment